Kintor Pharmaceutical Announces Successful Phase III Results for KX-826 in AGA Treatment

Key Highlights

• Phase III pivotal clinical trial for KX-826 tincture 1.0% in male adult androgenetic alopecia (AGA) meets primary endpoint
• Statistically significant and clinically meaningful efficacy demonstrated
• Excellent safety and tolerability confirmed, with no drug-related serious adverse events
• Potential for first-in-class approval in China and globally
• Plan to initiate NDA submission in China imminently
• Direct competition with Cosmo Pharmaceuticals, which also reported positive Phase III results for a similar drug
• Warning to investors: No assurance that other KX-826 products will be successfully developed and marketed

Detailed Report

Kintor Pharmaceutical Limited (Stock code: 9939) has announced the successful completion and top-line results of the Phase III stage of its pivotal clinical trial for KX-826 tincture 1.0%, targeting male adult androgenetic alopecia (AGA) in China. The company recently completed the enrollment of all subjects by the end of July 2025 and has now reported that the trial has reached its primary endpoint, marking a major milestone in the development of this novel treatment.

Clinical Trial Structure and Outcomes

• Trial Design: The pivotal study was a multi-center, randomized, double-blind, vehicle-controlled phase II/III study with adaptive designs, evaluating both the 1.0% and 0.5% concentrations of KX-826 tincture. The trial involved 26 clinical research centers across China and included a 24-week treatment period, followed by a 14-day safety observation.
• Enrollment: A total of 666 patients were enrolled in the Phase III stage.
• Efficacy: Both the 1.0% BID (twice daily) and 0.5% BID groups showed statistically significant increases in target area non-vellus hair counts (TAHC) compared to placebo:
  • 1.0% BID group: +15.33 hairs/cm² from baseline
  • 0.5% BID group: +14.46 hairs/cm² from baseline
  • Placebo group: +4.68 hairs/cm² from baseline
  • Difference from placebo: 1.0% BID group +10.65 hairs/cm² (P<0.0001), 0.5% BID group +9.78 hairs/cm² (P<0.0001)
• Safety: Both active groups demonstrated excellent safety and tolerability. No drug-related serious adverse events were observed, and there were no clinically significant differences in adverse event incidence among the study groups.

Scientific Mechanism and Competitive Position

KX-826 is a topical drug designed to block androgen-mediated signaling in targeted tissues by competing for androgen receptor binding. The compound’s effect is localized to the skin, with low transdermal absorption and rapid metabolism to low-activity compounds, effectively minimizing systemic safety risks.

The company notes that Cosmo Pharmaceuticals has also announced positive Phase III results for a similar topical androgen receptor inhibitor and is seeking marketing approval in the U.S. and EU. Both drugs are positioned as novel therapies for AGA, potentially offering safer and more effective treatment options compared to traditional therapies.

If approved, KX-826 would be the first new drug in nearly 40 years to break the dominance of minoxidil and finasteride for AGA treatment, filling a significant clinical gap and potentially capturing substantial market share.

Regulatory and Market Implications

• Kintor plans to communicate and initiate the NDA (New Drug Application) submission for KX-826 1.0% with Chinese drug regulatory authorities in the near term.
• The company aims to position KX-826 as the first-in-class drug for AGA treatment in China and globally, which could be a major price-sensitive event for investors, potentially driving share value upon successful regulatory approval.
• The breakthrough nature of the drug and its clinical results may disrupt the current AGA treatment market and could lead to significant commercial opportunities.

Investor Warning

Shareholders and potential investors should note that, apart from the cosmetic products of 826 topical anti-hair loss solution and acne cream, there is no assurance that other products of KX-826 will ultimately be successfully developed and marketed. Caution is advised when dealing in the shares of the company.

Leadership and Governance

• The Board is led by Dr. Youzhi Tong (Chairman, Executive Director, and CEO), with executive, non-executive, and independent non-executive directors providing oversight and governance.

Conclusion

This announcement represents a significant milestone for Kintor Pharmaceutical and could be highly price-sensitive. The successful completion of Phase III with positive results positions KX-826 as a potential new market leader in AGA treatment, pending regulatory approval. Investors should monitor developments closely, as approval and commercialization could materially impact share value.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. All clinical and regulatory outcomes are subject to risk and uncertainty. Investors should conduct their own due diligence and consult professional advisors before making any investment decisions.

View KINTOR PHARMA-B Historical chart here